Enanta Pharmaceuticals | ENTA - Trade Debtors


Enanta Pharmaceuticals reported $40.16M in Trade Debtors for its fiscal quarter ending in December of 2024.





Trade Debtors Change Date
AbbVie USD 12.77B 132M Sep/2025
Amgen USD 9.57B 1.08B Dec/2025
Anika Therapeutics USD 29.33M 661K Dec/2025
Arrowhead Research USD 218.87M 212.05M Dec/2025
AstraZeneca USD 19.05B 1.49B Dec/2025
BioCryst Pharmaceuticals USD 106.82M 15.49M Dec/2025
Biogen USD 1.85B 234M Sep/2025
Bristol-Myers Squibb USD 14.62B 485M Sep/2025
Enanta Pharmaceuticals USD 40.16M 1.52M Dec/2024
Gilead Sciences USD 4.91B 182M Dec/2025
GlaxoSmithKline GBP 7.76B 545M Dec/2025
Halozyme Therapeutics USD 441.27M 95.24M Dec/2025
Heron Therapeutics USD 89.59M 8.54M Dec/2025
Immunic USD 1.5M 50K Jun/2024
Incyte USD 1.02B 128.52M Dec/2025
Insmed USD 140.86M 75.6M Dec/2025
Ionis Pharmaceuticals USD 66M 41.39M Dec/2025
J&J USD 21.33B 3.72B Dec/2025
Karyopharm Therapeutics USD 26.18M 5.6M Dec/2025
Ligand Pharmaceuticals USD 58.1M 15.98M Sep/2025
Merck USD 12.12B 596M Sep/2025
Neurocrine Biosciences USD 686.8M 41.2M Dec/2025
Novartis USD 12.29B 3.3B Dec/2025
Novavax USD 106.45M 72.27M Dec/2025
Pfizer USD 18.12B 2.02B Sep/2025
PTC Therapeutics USD 181.62M 21.45M Dec/2025
Roche Holding CHF 11.9B 460M Dec/2025
Sarepta Therapeutics USD 398.23M 2.49M Dec/2025
Vertex Pharmaceuticals USD 2.05B 106.4M Dec/2025